Kinaxis is a buy, Laurentian Bank says

Ahead of next week’s first quarter 2018 financials from Kinaxis Inc. (Kinaxis Stock Quote, Chart, News: TSX:KXS), Laurentian Bank Securities analyst Nick Agostino is looking for evidence of accelerating subscription growth from the supply chain management company. The analyst is maintaining his rating of “Buy” with a target price of C$98.00.

Cloud-based SaaS provider Kinaxis will report its fiscal Q1/18 on May 2, with expectations of a healthy uptick in subscriptions, sales and earnings. Consensus estimates are calling for total sales of $37.3 million (all figures in US dollars unless noted) and adjusted EBITDA of $9.4 million, while Agostino’s estimates are a touch lower.

“We look for sales ($36.7 million) and EBITDA ($9.2 million) just below consensus, with EBITDA margin of 25.1 per cent and adj. EPS of $0.23 in line with consensus,” says the analyst in a client update on Thursday. “We estimate KXS ended Q1 with $166.0 million in net cash including $5.5 million in CFO (excl. w/c).”

Agostino expects the company’s subscription numbers to grow by 23 per cent, up from 19 per cent during the previous quarter. “Meeting our growth estimate would give us increased comfort in our modelled YoY growth acceleration through the balance of 2018 from an adj. low of 28 per cent to 34 per cent in Q4, and offer a further validation of the growing SIs contribution,” he says.

The analyst is hoping for management guidance on a number of issues: (1) an update on KXS’s SI channel partners; (2) an indication of pipeline prospects and customer wins, particularly in Asia and Europe; (3) an update on ARPU expansion; (4) a look at growth in deferred revenue to gauge new and existing customer wins; (5) details on the Deloitte/Merck market-specific collaboration capabilities for Kinaxis’ RapidResponse software; and (6) details on any measured impact from recent senior management hires.

Based on a valuation of 9x 2019E sales, Agostino asserts a target price of (C) $98.00, representing a projected 12-month return of 19.2 per cent at the time of publication.

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Tagged with: kxs
Jayson MacLean

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.

Recent Posts

Is Peloton Stock a Buy? (May, 2024)

Following news of a restructuring, Roth MKM analyst George Kelly has chopped his price target on Peloton (Peloton Stock Quote,… [Read More]

2 days ago

Is Ascend Wellness stock a buy?

Ahead of the company's first quarter results, Beacon analyst Russell Stanley thinks Ascend Wellness (Ascend Wellness Stock Quote, Chart, News,… [Read More]

2 days ago

Paradigm chops price target on Snipp Interactive

Following the company's fourth quarter results, Paradigm Capital analyst Daniel Rosenberg has cut his price target on Snipp Interactive (Snipp… [Read More]

2 days ago

It’s time to buy cannabis stocks, this analyst says

A major development came down the pipe this week at the U.S. Drug Enforcement Agency has reportedly decided to reschedule… [Read More]

3 days ago

Is Generac stock a buy?

Following the company's first quarter results, Roth MKM analyst Chip Moore remains neutral on Generac Holdings (Generac Holdings Stock Quote,… [Read More]

3 days ago

Bombardier is a buy, Desjardins says (May, 2024)

The stock has climbed slowly but surely since last October. But is there still money to be made on Bombardier?… [Read More]

3 days ago